Pharmatek Announces Official Opening of New Highly-Potent & Cytotoxic Development and Manufacturing Facility
SAN DIEGO, Calif. – September 17, 2008 – Pharmatek – a pharmaceutical chemistry development organization supporting the pharmaceutical industry – today announced the opening of its highly-potent and cytotoxic facility located in San Diego.
The 18,000 sq. ft. facility includes newly constructed analytical and formulation development laboratories and cGMP manufacturing suites dedicated to the development of highly-potent and cytotoxic drug product for early phase clinical trials.
“Highly-potent and cytotoxic compounds are among the most sensitive drugs to handle and produce.” said Kevin Rosenthal, director of manufacturing of Pharmatek. “Our primary goal when designing the facility was to optimize product quality while ensuring operator safety to guarantee our clients’ drug candidates move smoothly from discovery to clinical trials.”
The facility holds a State of California Food and Drug Branch (FDB) Drug Manufacturers License and is currently working on a number of highly-potent development projects. The FDB license authorizes Pharmatek to manufacture and ship clinical material from its state-of-the-art highly-potent and cytotoxic manufacturing and development site.
“The highly-potent facility is a significant addition to our service offering,” said Timothy Scott, president of Pharmatek. “We are always looking for ways to better meet our client’s drug development outsourcing needs, and the highly-potent and cytotoxic facility strengthens our ability to provide a broader level of services to our clients.”Leave a reply →